Iloprost
Other / unclassified targets PTGIR via activation
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | VENTAVIS | — | 2005-08-24 | fda.gov ↗ |
| Approved | US (FDA) | VENTAVIS | — | 2004-12-29 | fda.gov ↗ |
| Approved | EU (EMA) | Ventavis | — | 2003-09-15 | europa.eu ↗ |
Trials 66 · started per year
Also used as a comparator or background therapy in 8 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT03867097 Comparator | Mar → Aug 2019 | systemic sclerosis | Civi Biopharma, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02238535 Comparator | Sep 2014 → Mar 2016 | pulmonary hypertension | Meshalkin Research Institute of Pathology of Circulation | Unknown | No outcome recorded |
| Phase 2 | NCT01320878 Comparator | Oct 2007 → Jul 2009 | pulmonary hypertension | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00622687 Comparator | Sep 1997 → Dec 2003 | systemic sclerosis | Charite University, Berlin, Germany | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04040322 Comparator | Oct 2019 → Jun 2021 | Raynaud disease | Civi Biopharma, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03111212 Comparator | Jun 2019 → May 2021 | adult acute respiratory distress syndrome | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00120380 Comparator | Sep 2004 → May 2006 | hypertensive disorder | Hannover Medical School | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05204784 Comparator | Feb 2022 → Dec 2023 | Raynaud disease, chronic ulcer of skin, systemic sclerosis | Peter Korsten | Unknown | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 75 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iloprost | “Addition of a prostacyclin pathway agent (inhaled iloprost or oral selexipag) to ongoing dual therapy with an endothelin receptor antagonist and sildenafil as part of...” NCT07713914 ↗70“L608 is developed by Pharmosa Biopharm Inc. (PBI) as a new liposomal Iloprost formulation for inhalation use in the treatment of patients with WHO Group 1 PAH.” NCT06429930 ↗ “Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard” NCT05204784 ↗ “3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were injected into the common femoral artery.” NCT01774058 ↗ “20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer” NCT02032836 ↗ |
| Known as | Aurlumyn | ChEMBL registry synonym — accepted as the source's own label CHEMBL494 ↗ |
| Known as | BAYQ6252 | “lloprost(Ventavis,BAYQ6252, 20 µg/mL)” NCT02032836 ↗ |
| Known as | BAYQ6256 | “Iloprost (Ventavis inhaled, BAYQ6256)” NCT01469169 ↗ |
| Known as | Ciloprost | ChEMBL registry synonym — accepted as the source's own label CHEMBL494 ↗ |
| Known as | Endoprost | ChEMBL registry synonym — accepted as the source's own label CHEMBL494 ↗ |
| Known as | Ilomedin | “3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were injected into the common femoral artery.” NCT01774058 ↗ |
| Known as | Ventavis | “Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery” NCT00235521 ↗14“Ventavis® is the commercial brand name for inhaled iloprost in Brazil.” NCT07263958 ↗ “2 inhalations per day of 2.5 µg Iloprost \[Ventavis®\] per inhalation” NCT02482402 ↗ “iloprost inhalation solution (Ventavis) (5 μg)” NCT00302211 ↗ “Iloprost 10μg of inhaled iloprost (Ventavis®)” NCT03936140 ↗ “20μg (2ml) of inhaled iloprost (Ventavis®)” NCT04927039 ↗ “20μg(2ml) of inhaled iloprost (Ventavis®)” NCT02784899 ↗ “BAYQ6256 (Iloprost; Ventavis) Inhalation” NCT02032836 ↗ “Iloprost Inhalation Solution (Ventavis)” NCT00453414 ↗ “Iloprost Inhalation Solution (Ventavis)” NCT00109681 ↗ “Iloprost (Ventavis inhaled, BAYQ6256)” NCT01469169 ↗ “Ventavis (Iloprost, BAYQ6256)” NCT00414687 ↗ “Ventavis (Iloprost, BAYQ6256)” NCT00185315 ↗ “Iloprost (Ventavis)” NCT00927654 ↗ |
| Known as | ZK 00036374 | ChEMBL registry synonym — accepted as the source's own label CHEMBL494 ↗ |
| Known as | ZK-36374 | ChEMBL registry synonym — accepted as the source's own label CHEMBL494 ↗ |
| Action | Activate | “trials of inhaled prostacyclin agonists such as iloprost for the treatment of asthma” NCT01209533 ↗1“Prostanoid IP receptor agonist” CHEMBL494 ↗ |
| Modality | Other / unclassified | “oral iloprost, a prostacyclin analog” NCT00004786 ↗ |
| Route | Oral | “Patients receive oral iloprost or placebo twice daily for 6 weeks.” NCT00004786 ↗ |
| Target | PTGIR | “Prostanoid IP receptor agonist” CHEMBL494 ↗ |